Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

CYTK stock hub

Cytokinetics, Incorporated has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

CYTKis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

9.6B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

CYTK

In the news

Latest news · CYTK

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROEn/a

P25 -105.6P50 -46.5P75 -3.1

ROIC-62.9

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All CYTK market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

207

Groups with data

Currency

USD

Showing 207 of 207 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001061983
Company name	Cytokinetics, Incorporated
Country	United States
Country code	US
Cusip	23282W605
Employees	673
Employees Change	175%
Employees Change Percent	35.14
Enterprise value	$10.2B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2004-04-29
Isin	US23282W6057
Last refreshed	2026-05-10
Market cap	$9.6B
Market cap category	Mid-Cap
Price	$76.91
Price currency	USD
Rev Per Employee	157,228.83x
Sector	Healthcare
Sic	2834
Symbol	CYTK
Website	https://www.cytokinetics.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-8.67%
EV Sales Forward	74.36x
EV/Sales	96.35x
FCF yield	-5.74%
P/S ratio	90.44x
PS Forward	69.8x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	-290.73%
Gross Profit	$-307.6M
Net Income	$-829.6M
Net Income Growth Years	0%
Pretax Margin	-784.02%
Profit Per Employee	$-1.2M
ROA	-31.54
Roa5y	-25.94
ROCE	-59.6
ROIC	-62.88

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	25.34%
Cagr15y	16.13%
Cagr1y	132.91%
Cagr20y	2.82%
Cagr3y	24.93%
Cagr5y	25.99%
EPS Growth Years	0
Revenue Growth	450.6x
Revenue Growth Q	1,125.78x
Revenue Growth Quarters	7x
Revenue Growth Years	2x
Revenue Growth3 Y	2.57x
Revenue Growth5 Y	12.56x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.08
Assets	$1.3B
Cash	$818.6M
Current Assets	$839.5M
Current Liabilities	$199.2M
Debt	$1.4B
Equity	$-826.6M
Interest Coverage	-5.6
Liabilities	$2.1B
Long Term Assets	$434M
Long Term Liabilities	$1.9B
Net Cash	$-625.1M
Net Cash By Market Cap	$-6.53
Tangible Book Value	$-826.6M
Tangible Book Value Per Share	$-6.65
WACC	6.33

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	4.21
Net Working Capital	$-82.9M
Quick ratio	4.14
Working Capital	$640.3M
Working Capital Turnover	$0.15

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-4.46%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	856.59%
1Y total return	132.78%
200-day SMA	58.54
3Y total return	95.01%
50-day SMA	64.49
50-day SMA vs 200-day SMA	50over200
5Y total return	217.42%
All Time High	110.3
All Time High Change	-30.24%
All Time High Date	2024-01-08
All Time Low	3.05
All Time Low Change	2,421.64%
All Time Low Date	2014-10-13
ATR	3.76
Beta	0.38
Beta1y	0.26
Beta2y	0.81
Ch YTD	21.04
High	78.8
High52	80.2
High52 Date	2026-05-05
High52ch	-4.1%
Low	74.51
Low52	29.31
Low52 Date	2025-05-15
Low52ch	162.4%
Ma50ch	19.26%
Premarket Change Percent	0.94
Premarket Price	$74.99
Premarket Volume	968
Price vs 200-day SMA	31.39%
RSI	68.93
RSI Monthly	65.61
RSI Weekly	70.06
Sharpe ratio	1.6x
Sortino ratio	3.58
Total Return	-4.46%
Tr YTD	21.04
Tr15y	842.52%
Tr1m	17.46%
Tr1w	21.41%
Tr3m	23.37%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	19
Analyst Count Top	11
Analyst Price Target Top	$85.73
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$-1.65
Earnings Revenue Estimate	8,485,280x
Earnings Revenue Estimate Growth	437.38x
Operating Income	$-640.2M
Operating margin	-605.1
Price target	$93.95
Price Target Change	$22.16
Price Target Change Top	$11.47

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	123,879,629%
Float Percent	99.56%
Net Borrowing	316,096,000
Shares Insiders	0.41%
Shares Institutions	112.47%
Shares Out	124,432,565
Shares Qo Q	2.64%
Shares Yo Y	4.46%
Short Float	12.02%
Short Ratio	7.63
Short Shares	11.96

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$-668.1M
Average Volume	3,213,469.4x
Bv Per Share	-6.65
CAPEX	$-25.1M
Ch10y	856.6
Ch15y	842.5
Ch1m	17.46
Ch1w	21.41
Ch1y	132.8
Ch20y	74.4
Ch3m	23.37
Ch3y	95.01
Ch5y	217.4
Ch6m	27.84
Change	3.53%
Change From Open	3.22
Close	74.29
Days Gap	0.3
Depreciation Amortization	11,203,000
Dollar Volume	445,445,415.3
Earnings Date	2026-05-05
Earnings Time	amc
EBIT	$-640.2M
EBITDA	$-629M
EPS	$-6.84
F Score	3
FCF	$-548.9M
FCF EV Yield	-5.38x
FCF Per Share	$-4.41
Financing CF	527,474,000
Fiscal Year End	December
Founded	1,997
Investing CF	56,202,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-05
Last Report Date	2026-03-31
Last Split Date	2013-06-25
Last Split Type	Reverse
Last10k Filing Date	2026-02-26
Ma150	63.62
Ma150ch	20.89%
Ma20	66.9
Ma20ch	14.97%
Net CF	58,899,000
Next Earnings Date	2026-08-06
Open	74.51
Optionable	Yes
Position In Range	55.94
Post Close	76.91
Postmarket Change Percent	-0.6
Postmarket Price	$76.45
Ppne	156,983,000
Pre Close	74.29
Price Date	2026-05-08
Relative Volume	1.8x
Revenue	105,815,000x
SBC By Revenue	112.58x
Share Based Comp	119,131,000
Tr20y	74.4%
Tr6m	27.84%
Us State	California
Volume	5,791,775
Z Score	-3.29

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does CYTK pay a dividend?

Capital-return profile for this ticker.

Performance

CYTK stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns CYTK?

Insider, institutional, and short-interest positioning.

Institutional ownership

+112.5%

Float: +99.6% of shares outstanding

Insider ownership

+0.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

CYTK momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

68.9

Neutral momentum band

Price vs 200-day MA

+31.4%

50/200-day relationship not available

Beta (5Y)

0.38

Less volatile than the market

Sharpe ratio

1.59

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About CYTK

Hub-level FAQ points readers to the deeper analysis pages.

What is the current CYTK stock rating?

Cytokinetics, Incorporated is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full CYTK analysis?

The full report lives at /stocks/CYTK/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for CYTK?

The latest report frames CYTK around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the CYTK page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.